Supporting Information

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

Ashraf K. El-Damasy ^{a,b 1*}, Heewon Jin ^{a, 1}, Jung Woo Park^c, Hyun Ji Kim ^a, Hanan Khojah^d, Seon Hee Seo ^e, Ju-Hyeon Lee^a, Eun-Kyoung Bang ^a, Gyochang Keum ^{a,f*}

^a Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea

^b Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

^c Center for Supercomputing Applications, Div. of National Supercomputing R&D, Korea Institute of Science and Technology Information, 245, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea

^d Department of Pharmacognosy, College of Pharmacy, Jouf University, P.O. Box 2014, Sakaka, Al-Jouf, Saudi Arabia

^e Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea

^f Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea

¹ These authors contributed equally to this work.

Corresponding author:

Ashraf K. El-Damasy, E-mail: <u>ph_karem2000@mans.edu.eg</u>, <u>phkarem2006@gmail.com</u> Gyochang Keum, E-mail: <u>gkeum@kist.re.kr</u>

Contents	Pages
1) Experimental section	2–3
2) ¹ H NMR and ¹³ C NMR spectra	4–10
3) HRMS charts	11–13
4) 2D binding mode & bioavailability radar of 2b	14
5) NCI data	15–19
6) References	20

1. Experimental section

1.1. General

All reactions and manipulations were conducted utilizing standard Schlenk techniques. All solvents and reagents were obtained from commercial suppliers and were used without further purification. The reaction progress was monitored on TLC plate (Merck, silica gel 60 F_{254}). Flash column chromatography was carried out using silica gel (Merck, 230–400 mesh) and the eluent solvents are indicated as a mixed solvent with either given percentage or volume-to-volume ratios. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer, using the proper deuterated solvents, as noted. Chemical shifts (δ) are given in parts per million (ppm) upfield from tetramethylsilane (TMS) as internal standard. s, d, t, and m refer to singlet, doublet, triplet and multiplet, respectively, and coupling constants (*J*) are reported in hertz (Hz). High resolution mass spectra (HRMS) were recorded on JMS 700 (Jeol, Japan) mass spectrometer, with magnetic sector-electric sector double focusing mass analyzer, and FAB+ ion mode. The purity of all final compounds was found to be > 95%, as determined by ¹H NMR. 3-(Trifluoromethyl)aniline and 3,5-bis(trifluoromethyl)aniline were commercially available, while the cyclic amine bearing anilines were synthesized adopting the reported procedure \.

1.2. 6-(2-Methoxyphenyl)benzo[d]thiazol-2-amine (1)

A solution of 2-methoxyphenyl boronic acid (199 mg, 1.31 mmol) in dimethoxyethane:H₂O (3:1, v/v, 3 mL) was added to a stirred solution of 6-bromo-2-aminothiazol (200 mg, 0.873 mmol), NaHCO₃ (220 mg, 2.619 mmol), and Pd(dppf)Cl₂·CH₂Cl₂ (143 mg, 0.20 mmol) in dimethoxyethane:H₂O (3:1, v/v, 1 mL). The reaction mixture was stirred at room temperature for 85 min at 80–85 °C. After the reaction completion, the solvent was evaporated under vacuum, and the residue was filtered by celite pad. The filtrate was evaporated and the resulting residue was purified by column chromatography using (33–50% ethyl acetate in hexane) to afford the title compound as a brown solid; 194 mg (86.6%); ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 1.4 Hz, 1H), 7.58 (d, *J* = 8.3 Hz, 1H), 7.48 (dd, *J* = 8.3, 1.6 Hz, 1H), 7.35–7.30 (m, 2H), 7.04 (td, *J* = 7.5, 0.84 Hz, 1H), 7.00 (d, *J* = 8.2 Hz, 1H), 5.42 (br. s, 1H), 3.83 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 156.4, 146.7, 133.8, 130.9, 129.9, 129.2, 128.8, 128.3, 122.2, 120.9, 117.4, 111.3, 55.6.

1.3. General procedure for synthesis of compounds 2a-f

A solution of compound 1 (200 mg, 0.78 mmol) and 1,1'-carbonyldiimidazole (253 mg, 1.56 mmol) in anhydrous dimethylformamide (2 mL) was stirred at room temperature for 15 h. Then, the appropriate aniline (1.56 mmol) was added and the reaction mixture was heated to 100 °C for 2.5 h. After cooling to room temperature, the reaction was quenched with water (20 mL). The aqueous layer was extracted with ethyl acetate (3×30 mL), and the organic layers were combined, washed with water and brine, dried over anhydrous Na₂SO₄, and filtered. The solvent was evaporated under vacuum, and the resultant residue was purified by flash column chromatography using the proper eluent to afford the target compounds in pure form.

1.3.1. 1-(6-(2-Methoxyphenyl)benzo[d]thiazol-2-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea (2a)

Column chromatography was performed using 5% methanol in DCM. White solid (28.1% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.36–7.31 (m, 4H), 7.05–6.99 (m, 2H), 6.86 (d, J = 8.4 Hz, 2H), 3.82 (s, 3H), 3.17 (t, J = 5.0 Hz, 4H), 2.61 (t, J = 4.6 Hz, 4H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 156.5, 152.8, 148.3, 147.8, 134.1, 131.0, 130.9, 130.0, 129.8, 128.7, 128.1, 122.2, 122.1,121.0, 119.3, 116.8, 111.3, 55.6, 55.0, 49.3, 46.0; HRMS (FAB) m/z calcd for C₂₆H₂₈N₅O₂S [M+H]⁺: 474.1963, found: 474.1960.

1.3.2. 1-(4-(4-Ethylpiperazin-1-yl)phenyl)-3-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)urea (2b)

Column chromatography was performed using 3–7% methanol in dichloromethane (DCM). White solid (23.1% yield); ¹H NMR (400 MHz, CDCl₃) δ 10.77 (br. s, 1H), 7.87 (s, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.32–7.26 (m, 4H), 7.04–6.97 (m, 2H), 6.83 (d, *J* = 7.6 Hz, 2H), 3.81 (s, 3H), 3.14 (s, 4H), 2.59 (s, 4H), 2.48 (q, *J* = 6.9 Hz, 2H), 1.13 (t, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.5, 156.5, 152.8, 148.4, 147.7, 134.1, 131.1, 130.0, 129.8, 128.7, 128.1, 122.1, 122.0, 121.9, 121.0, 119.2, 116.7, 111.3, 55.6, 52.8, 52.4, 49.5, 12.0; HRMS (FAB) m/z calcd for C₂₇H₃₀N₅O₂S [M+H]⁺: 488.2120, found: 488.2117.

1.3.3. 1-(6-(2-Methoxyphenyl)benzo[d]thiazol-2-yl)-3-(4-morpholinophenyl)urea (2c)

Column chromatography was performed using 3–7% methanol in DCM. White solid (23% yield); ¹H NMR (400 MHz, DMSO- d_6) δ 10.85 (br. s, 1H), 8.96 (s, 1H), 7.98 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.39–7.34 (m, 4H), 7.14 (d, J = 8.4 Hz, 1H), 7.05 (t, J = 7.2 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.36 (s, 4H), 3.09 (s, 4H); ¹³C NMR (100 MHz, DMSO- d_6) δ 160.4, 156.6, 152.6, 147.8, 133.4, 131.6, 131.1, 130.6, 130.1, 129.2, 128.0, 122.4, 121.3, 120.8, 119.1, 116.5, 116.4, 112.2, 60.8, 59.0, 56.0.

1.3.4. 1-(6-(2-Methoxyphenyl)benzo[d]thiazol-2-yl)-3-(3-(trifluoromethyl)phenyl)urea (2d)

Column chromatography was performed using ethyl acetate-hexane (1:3, v/v). White solid (43% yield); ¹H NMR (400 MHz, DMSO- d_6) δ 11.27 (br. s, 1H), 9.59 (s, 1H), 8.09 (s, 1H), 7.99 (s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.52 (dd, J = 8.4, 1.2 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.36 (s, 1H), 7.34 (s, 1H), 7.13 (d, J = 8.4 Hz, 1H), 7.05 (t, J = 7.4 Hz, 1H), 3.79 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6) δ 156.6, 140.2, 133.7, 132.5, 131.0, 130.5, 130.3, 130.0, 129.9, 129.2, 128.2, 126.0, 123.3, 123.0, 122.6, 121.3, 119.6, 119.5, 115.3, 115.3, 112.2, 56.0; HRMS (FAB) m/z calcd for C₂₂H₁₇F₃N₃O₂S [M+H]⁺: 444.0993, found: 444.0992.

1.3.5. 1-(3,5-Bis(trifluoromethyl)phenyl)-3-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)urea (2e)

Column chromatography was performed using 1% methanol in DCM. White solid (76% yield); ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.89 (br. s, 1H), 9.96 (s, 1H), 8.31 (s, 2H), 7.96 (s, 1H), 7.71 (s, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.52 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 1H), 7.05 (t, *J* = 7.4 Hz, 1H), 3.79 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 156.6, 141.9, 133.8, 131.7, 131.4, 131.1, 131.0, 130.7, 129.9, 129.3, 128.4, 125.1, 122.8, 122.4, 121.3, 119.0, 115.6, 112.2, 56.0; HRMS (FAB) m/z calcd for C₂₃H₁₆F₆N₃O₂S [M+H]⁺: 512.0867, found: 512.0866.

1.3.6. 1-(6-(2-Methoxyphenyl)benzo[d]thiazol-2-yl)-3-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)urea (**2f**) Column chromatography was performed using ethyl acetate-hexane (1:1, v/v). Yellow solid (18.4% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 1.6 Hz, 1H), 7.91 (br. s, 1H), 7.84–7.73 (m, 3H), 7.63 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.40–7.36 (m, 2H), 7.09 (d, *J* = 7.2 Hz, 1H), 7.04 (d, *J* = 8.8 Hz, 1H), 3.87 (s, 3H), 3.76 (t, *J* = 4.4 Hz, 4H), 3.66 (s, 2H), 2.52 (t, *J* = 4.4 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 156.5, 152.8, 148.4, 147.8, 134.3, 134.1, 131.0, 131.0, 130.1, 129.7, 128.8, 128.7, 128.2, 128.1, 122.3, 122.1, 121.0, 119.3, 116.8, 111.3, 55.6, 55.0, 49.3, 46.0; HRMS (FAB) m/z calcd for C₂₇H₂₆F₃N₄O₃S [M+H]⁺: 543.1677, found: 543.1681.

1.4. In vitro biological evaluations

1.4.1. In vitro kinase screening

Reaction Biology Corporation (RBC) Kinase HotSpotSM service was employed for biochemical kinase evaluation of the target compounds following the reported assay protocol ⁵.

1.4.2. In vitro cell based assays

1.4.2.1. Preliminary MTT evaluation of antiproliferative activity

The antiproliferative activity of the target benzothiazoles was assessed against human leukemia K562 cancer cell as well as L132 normal cell line, using the MTT assay adopting the reported assay protocols ⁶.

1.4.2.2. Anti-cancer screening at NCI

The anticancer screening of certain selected target compounds over a full panel of 60-human cancer cell lines was conducted at the National Cancer Institute (NCI), Bethesda, Maryland, USA using Sulforhodamine B (SRB) assay adopting the standard protocol ⁷.

1.5. In silico studies


1.5.1. Molecular docking


The docking models of compound **2b** were constructed utilizing the X-ray crystal structure of BCR-ABL^{WT} (PDB: 2GQG)⁸ or BCR-ABL^{T3151}(PDB: 2Z60)⁹, in its DFG-in conformation using Discovery Studio 2022 (DS). The protein structure of BCR-ABL^{WT} and BCR-ABL^{T3151} were prepared for docking by employing protocol "prepare protein", and ligands were prepared through protonation at pH 7.4 and energy minimization. The binding site was defined based on the ligand interactions with BCR-ABL kinase domain. The ligands were docked into the defined binding sites using the CDOCKER algorithm, and the ligand pose with the best score was selected for analysis of the binding mode.


1.5.2. Bioavailiability Predicition


The bioavailability prediction of compound **2b** was assessed at http://www.swissadme.ch/index.php (accessed on 10 December 2022).


2) ¹H NMR and ¹³C NMR spectra
























3) HRMS charts









4) 2D binding mode & bioavailability radar of 2b




Figure S1. 2D binding mode of compound **2b** with BCR-ABL^{WT} and BCR-ABL^{T3151}. Various interactions are depicted by different color legends. The inhibitor is shown by line, interacting residues by colored sphere, and interactions by dash lines.






Figure S2. The bioavailability radar of 2b.


5) NCI data



		20
Panel/Cell Line	Growth Percent	Mean Growth Percent - Growth Percent
Leukemia CCRF-CEM	-17.32	
HL-60(TB)	-74.14	
K-562	-67.39	
MOLT-4	-51.72	
RPMI-8226	-32.99	
SR	-37.99	
Non-Small Cell Lung Cancer		
A549/ATCC	-77.13	
EKVX	-68.43	
HOP-62	-66.15	
HOP-92	2.16	
NCI-H226	56.60	
NCI-H23	-16.82	
NCI-H322M	-85.96	
NCI-H460	-64.36	
NCI-H522 Colon Cancer	-78.09	
	72.10	
COLO 205 HCC-2998	-73.18 -88.13	
HCT-116	-82.33	
HCT-15	-83.17	
HT29	-92.03	
KM12	-83.47	
SW-620	-69.98	
CNS Cancer		
SF-268	-59.43	
SF-295	-79.95	
SF-539	-82.57	
SNB-19	-82.82	
SNB-75	-19.81	
U251	-86.98	
Melanoma		
LOX IMVI	-86.40	
MALME-3M	-80.30	
M14 MDA-MB-435	-70.13 -85.49	
SK-MEL-2	-65.48	
SK-MEL-2 SK-MEL-28	-79.30	
SK-MEL-5	-98.79	
UACC-257	-71.94	
UACC-62	-85.26	
Ovarian Cancer		
IGROV1	-71.35	
OVCAR-3	-90.46	
OVCAR-4	-76.12	
OVCAR-5	-11.52	
OVCAR-8	-52.55	
NCI/ADR-RES	-67.32	
SK-OV-3	-12.52	
Renal Cancer	00.00	
786-0 A498	-80.66 70.17	
ACHN	-95.48	
RXF 393	-74.15	
SN12C	-82.09	
TK-10	-48.01	
UO-31	-91.59	
Prostate Cancer		
PC-3	-83.78	
DU-145	-84.44	
Breast Cancer		
MCF7	-70.76	
MDA-MB-231/ATCC	-73.96	
HS 578T	-23.18	
BT-549 T 47D	31.65	
T-47D MDA-MB-468	-45.42 -76.67	
MDA-WB-400	-10.07	
Mean	-60.96	
Delta	37.83	
Range	168.96	
	1	0 100 50 0 -50 -100 -150


	_						-	centration							
Panel/Cell Line	Time Zero	Ctrl	-8.0	Mean -7.0		Densiti -5.0	-4 0	-8.0	-7.0	ercent G -6.0	rowth -5.0	-4.0	GI50	TGI	LC50
Leukemia CCRF-CEM HL-60(TB) K-562	0.623 0.842 0.226	2.866 2.792 2.152	2.809 2.774 2.181	2.829 2.804 1.885	2.564 2.553 0.397	0.282 0.246 0.088	0.220 0.269 0.137	97 99 101	98 101 86	87 88 9	-55 -71 -81	-65 -68 -40	1.81E-6 1.73E-6 2.93E-7	4.09E-6 3.58E-6 1.34E-6	9.25E-6 7.39E-6
MOLT-4 RPMI-8226 SR Non-Small Cell Lung	0.803 0.767 0.367	2.963 2.614 1.200	2.709	3.017 2.712 1.150		0.235 0.397 0.206	0.268 0.318 0.227	99 105 91	103 105 94	92 95 76	-71 -48 -44	-67 -59 -38	1.80E-6 2.06E-6 1.65E-6	3.67E-6 4.60E-6 4.31E-6	7.45E-6 1.48E-5 > 1.00E-4
A549/ATCC EKVX HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H480 NCI-H480	0.524 0.747 1.233 1.055 0.661 1.063 0.337 1.256	2.482 2.375 1.968 2.311 2.162 2.402 3.047 2.983	2.454 2.146 1.893 2.314 2.091 2.367 3.123 2.765	2.560 2.157 1.873 2.328 2.004 2.234 3.194 2.786	2.028 1.752 2.283 1.909 2.149 2.965	0.233 0.133 0.028	0.036 0.139 0.406 0.415 0.076 -0.020 -0.006 0.196	99 86 90 100 95 97 103 87	104 87 101 90 87 105 89	107 79 71 98 83 81 97 90	-86 -80 -52 -52 -65 -87 -92 -76	-93 -81 -67 -89 -100 -100 -84	1.98E-6 1.51E-6 1.47E-6 2.09E-6 1.67E-6 1.53E-6 1.77E-6 1.75E-6	3.59E-6 3.12E-6 3.75E-6 4.52E-6 3.05E-6 3.03E-6 3.27E-6 3.50E-6	6.51E-6 6.44E-6 9.55E-6 9.77E-8 7.94E-6 5.99E-6 6.01E-6 7.01E-6
Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620	0.670 0.631 0.243 0.225 0.362 0.508 0.331	2.527 2.454 2.129 1.765 2.517 2.744 2.097	2.411 2.350 2.110 1.603 2.453 2.797 2.089	2.504 2.366 2.193 1.628 2.369 2.812 2.223		0.080 0.016 0.006	0.104 0.036 -0.022 -0.043 0.002 0.067 0.008	94 99 89 97 102 100	99 95 103 91 93 103 107	101 99 86 63 69 94 105	-71 -87 -94 -98 -90 -86 -86	-85 -94 -100 -100 -100 -87 -98	1.97E-6 1.83E-6 1.58E-6 1.20E-6 1.31E-6 1.75E-6 1.94E-6	3.85E-6 3.39E-6 3.01E-6 2.47E-6 2.70E-6 3.33E-6 3.55E-6	7.51E-6 6.30E-6 5.71E-6 5.08E-6 5.57E-6 6.33E-6 6.48E-6
CNS Cancer SF-268 SF-295 SF-539 SNB-19 SNB-75 U251	0.709 0.631 0.873 0.758 0.792 0.534	2.297 2.340 2.525 2.517 1.768 2.305	2.189 2.133 2.346 2.535 1.604 2.311	2.198 2.247 2.386 2.624 1.640 2.372	2.256 2.207 2.306 2.691 1.582 2.061	0.166 0.027 0.059 0.111 0.027 0.013	0.156 0.020 0.017 0.022 0.009 -0.030	93 88 89 101 83 100	94 95 92 106 87 104	97 92 87 110 81 86	-77 -96 -93 -85 -97 -98	-78 -97 -98 -97 -99 -100	1.87E-6 1.68E-6 1.60E-6 2.03E-6 1.49E-6 1.57E-6	3.63E-6 3.09E-6 3.03E-6 3.65E-6 2.86E-6 2.94E-6	7.03E-6 5.71E-6 5.75E-6 6.59E-6 5.48E-6 5.51E-6
Melanoma LOX IMVI MALME-3M MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62	0.364 0.701 0.514 0.454 1.090 0.836 0.816 1.087 0.929	2.746 1.183 1.903 2.584 2.445 2.202 3.329 2.269 2.892		2.588 1.136 1.891 2.491 2.484 2.153 3.339 2.393 2.802	2.470 2.491 2.141 3.235 2.433	0.023 0.018 0.195 0.077 0.012 0.188	-0.018 0.232 -0.001	93 92 94 97 92 96 100 99	93 90 96 103 96 100 110 95	93 90 89 95 103 96 96 114 101	-92 -82 -96 -82 -91 -99 -83 -87	-97 -93 -100 -100 -79 -100 -100 -90 -96	1.70E-6 1.71E-6 1.62E-6 1.71E-6 1.74E-6 1.76E-6 1.73E-6 2.11E-6 1.87E-6	3.17E-6 3.34E-6 3.03E-6 3.14E-6 3.20E-6 3.12E-6 3.79E-6 3.45E-6	5.92E-6 6.54E-6 5.74E-6 6.71E-6 6.04E-6 5.63E-6 6.81E-6 6.36E-6
Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3	0.481 0.459 0.710 0.789 0.593 0.529 1.180	1.995 1.788 1.555 1.857 2.439 2.011 2.536		2.074 1.854 1.516 1.793 2.635 1.933 2.492		0.108	0.043 0.033 0.044 0.017 0.061 0.058 -0.007	101 104 91 82 102 98 92	105 105 95 94 111 95 97	97 89 88 97 106 90 92	-77 -91 -81 -86 -82 -82 -82 -75	-91 -93 -94 -98 -90 -89 -100	1.87E-6 1.64E-6 1.68E-6 1.90E-6 1.99E-6 1.72E-6 1.79E-6	3.61E-6 3.11E-6 3.31E-6 3.37E-6 3.66E-6 3.35E-6 3.55E-6	6.99E-6 5.90E-6 6.53E-6 6.33E-6 6.74E-6 6.55E-6 7.05E-6
Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31	0.745 1.461 0.385 0.888 0.554 0.939 0.610	2.694 2.128 1.586 1.518 2.316 1.899 1.813	2.090 1.563 1.544 2.273	2.728 2.098 1.642 1.561 2.336 1.856 1.625	2.074	0.050 0.397 -0.008 0.145 0.084 0.032 0.038	0.042 0.153 -0.031 0.049 0.051 0.010 0.020	94 94 104 98 92 87	102 96 105 107 101 96 84	99 92 97 90 95 121 82	-93 -73 -100 -84 -85 -97 -94	-94 -90 -100 -94 -91 -99 -97	1.80E-6 1.80E-6 1.74E-6 1.70E-6 1.77E-6 2.12E-6 1.52E-6	3.28E-6 3.61E-6 3.11E-6 3.30E-6 3.37E-6 3.60E-6 2.92E-6	5.98E-6 7.27E-6 5.58E-6 6.40E-6 6.40E-6 6.11E-6 5.63E-6
Prostate Cancer PC-3 DU-145	0.671 0.393	2.722 1.779		2.637 1.812		0.138 0.040	0.111 -0.001	96 102	96 102	94 95	-80 -90	-84 -100	1.79E-6 1.74E-6	3.47E-6 3.26E-6	6.74E-6 6.08E-6
Breast Cancer MCF7 MDA-MB-231/ATCC HS 578T BT-549 T-47D MDA-MB-468	0.440 0.663 1.019 1.227 0.976 0.982	2.461 2.145 1.956 2.206 2.089 1.980	2.152 2.017 2.022 1.949	2.210 2.137 1.977 2.186 2.018 2.043		0.088 0.094 0.519 0.343 0.373 0.266	0.063 0.096 0.420 0.196 0.304 0.174	86 100 107 81 87 92	88 99 102 98 94 106	67 92 91 96 78 112	-80 -86 -49 -72 -62 -73	-86 -86 -59 -84 -69 -82	1.31E-6 1.72E-6 1.95E-6 1.88E-6 1.58E-6 2.17E-6	2.86E-6 3.28E-6 4.45E-6 3.73E-6 3.61E-6 4.03E-6	6.25E-6 6.28E-6 1.25E-5 7.39E-6 8.23E-6 7.51E-6





HL-60(TB) -3 K-562 -1 RPMI-8226 -1 SR -22 Non-Small Cell Lung Cancer -4 A549/ATCC 11 EKVX 11 HOP-62 -2 HOP-792 -4 NCI-H226 11 NCI-H228 11 NCI-H228 12 NCI-H228 14 NCI-H228 14 NCI-H228 15 NCI-H322M 16 NCI-H322M 17 NCI-H322M 18 NCI-H322M 19 NCI-H52 -5 Colon Cancer 11 GOLO 205 -8 HCT-15 14 HCT-15 16 HT29 17 SW-620 11 CNS Cancer 17 SF-539 28 SNB-19 22 SNB-75 12 U251 11 M14	.89 .47 .97 .85 .91 .77 .73 .67 .58 .46 .93 .38 .32 .90 .89 .89 .83 .85 .74 .76 .63 .88 .85 .88 .88 .88 .88 .88			
HL-60(TB) -3. K-662 -1. MOLT-4 -11. RPMI-8226 -1. SR -22. Non-Small Cell Lung Cancer -4. A549/ATCC 11. EKVX 11. HOP-82 -2. HOP-82 -2. HOP-82 -2. NCI-H238 11. NCI-H228 11. NCI-H228 -2. Colon Cancer -2. COLO 205 -8. HCC-2998 11. HCT-15 12. HCT-15 13. HCT-15 14. HCT-15 14. HCT-15 14. HCT-15 14. MALME-30 11. SW-620 11. CNS Cancer -2. SF-288 11. SF-288 11. SK-MEL-30 24. MALME-33M -11. MALME-335 11. MALME-3435 11. MALME-33 13.	.47 .97 .85 .91 .77 .78 .67 .58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
K-562 -11 RPMI-8226 -11 SR -22 Non-Small Cell Lung Cancer -26 A549/ATCC 11 HOP-62 -1 HOP-92 -2 NCI-H226 11 NCI-H226 11 NCI-H322M 12 Colo Cancer -20 COLO 205 -8 HCC-2998 1 HCT-116 -4 HCT-15 12 HT29 -4 SW-620 11 CNS Cancer -5 SF-285 -1 SNB-75 2 U251 12 MALME-33M -11 MALME-33 11 MALME-33 11 MALME-33 11 S	.97 .85 .91 .77 .73 .87 .58 .46 .93 .32 .32 .38 .32 .38 .32 .89 .89 .89 .89 .89 .85 .74 .76 .63 .88 .85			
MOLT-4 -11 RPMI-8226 -1 SR -22 Non-Small Cell Lung Cancer A5490/ATCC A5490/ATCC 11 HOP-82 HOP-92 NCI-H226 11 NCI-H228 11 NCI-H322M 12 NCI-H423 13 NCI-H423 14 NCI-H423 15 NCI-H522 Colon Cancer COLO 205 -8 HCT-116 HCT-115 HT29 KM12 SW-620 11 SF-268 11 SF-268 11 SF-269 SF-539 SF-549 SF-539 -1 SF-7539 -1 M4LME-3M -11 MALME-3M -11 MDA-MB-435 11 MCA-M	.05 .01 .77 .77 .58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .63 .88 .88			
RPMI-8226 -1 SR -2 Non-Small Cell Lung Cancer -2 A549/ATCC 11 HOP-82 -2 HOP-82 -2 HOP-82 -2 HOP-82 -2 NCI-H226 11 NCI-H322M 12 NCI-H480 -2 NCI-H522 -2 Colon Cancer -2 COLO 205 -8 HCC-2998 1 HCT-15 14 HCT-15 14 HCT-15 14 HCT-16 -4 HT29 -4 KM12 5 SW-620 11 CNS Cancer -5 SF-295 -1 SNB-75 10251 U251 12 MALME-3M -11 M14 10 MDA-MB-435 11 MALME-3M -12 MEL-5 -8 UACC-257 <t< td=""><td>.01 .77 .78 .67 .58 .46 .93 .38 .32 .39 .89 .89 .89 .84 .85 .74 .76 .63 .88 .88</td><td></td><td></td><td></td></t<>	.01 .77 .78 .67 .58 .46 .93 .38 .32 .39 .89 .89 .89 .84 .85 .74 .76 .63 .88 .88			
SR -22 Non-Small Cell Lung Cancer A549/ATCC A549/ATCC 11 HOP-82 -1 HOP-82 -1 HOP-82 -1 HOP-82 -1 NCI-H226 11 NCI-H228 12 NCI-H322M 12 NCI-H522 -2 Colon Cancer -2 COLO 205 -8 HCC-2998 11 HCT-116 -4 HCT-15 -6 HT29 -7 KM12 -3 SW-820 11 CNS Cancer -2 SF-295 -1 SF-295 -1 SF-539 -2 SNB-75 -2 SNB-75 -2 SNB-75 -2 SNB-75 -1 MALME-3M -1 MALME-3M -1 MALME-3M -1 MALME-3M -1 SK-MEL-2	.77 .73 .67 .58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
Non-Small Cell Lung Cancer A549/ATCC 11 AVEXA 11 HOP-82 HOP-82 HOP-82 NCI-H236 11 NCI-H322M 11 NCI-H322M 11 NCI-H423 Colon Cancer COLO 205 -8 HCC-1998 1 HCT-15 -1 HCT-15 -1 HCT-15 -1 HT29 -1 KM12 -3 SW-820 1 CNS Cancer -3 SF-268 11 SF-269 -4 SF-269 -5 SNB-19 -21 SNB-75 -12 U251 11 M14 11 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-3 -8 UACC-257 -1 UACC-262 10 <	.73 .67 .58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88			
A549/ATCC 11 EKVX 11 HOP-82 - HOP-82 - NCI-H226 1 NCI-H226 1 NCI-H322M 11 NCI-H480 - NCI-H522 - Colon Cancer - COLO 205 - HCC-2998 1 HCT-15 1 HCT-16 1 HCT-15 1 HCT-17 1 HCT-17 1 HCT-18 1 HCT-18 1 HCT-18 1 HCT-18 1 HCT-19 1 H	.67 .58 .46 .93 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88			
EKVX 11 HOP-82 HOP-82 NCI-H226 11 NCI-H228 12 NCI-H322M 13 NCI-H460 NCI-H452 Colon Cancer COLO 205 -8 HCC-2998 11 HCT-116 HCT-15 HT29 KM12 SW-620 11 SF-288 11 SF-289 SNB-75 U251 12 Melanoma -1 LOX IMVI MALME-3M -1 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 11 MCK-REL-2 -1 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-28 3 MCMCAC-62 10 OVCAR-8 2	.67 .58 .46 .93 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88			
HOP-62 HOP-92 NCI-H226 11 NCI-H322M 12 NCI-H322M 13 NCI-H322M 14 NCI-H322M 14 NCI-H460 NCI-H522 Colon Cancer COLO 205 8 HCT-15 14 HCT-15 14 HCT-15 14 HCT-15 14 HCT-15 14 HCT-15 15 HCT-16 14 HCT-15 14 HCT-15 15 HCT-16 14 HCT-15 14 HCT-15 14 HCT-15 15 SK-MEL-2 16 SK-MEL-2 17 MALME-3M 11 MAC-257 14 UACC-257 14 UACC-257 14 UACC-257 14 UACC-257 14 </td <td>.58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82</td> <td></td> <td></td> <td></td>	.58 .46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
HOP-92	.46 .93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
NCI-H226 11 NCI-H23 11 NCI-H322M 11 NCI-H322M 12 NCI-H322M 11 NCI-H322M 12 Colon Cancer	.93 .38 .32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
NCI-H23 11 NCI-H322M 12 NCI-H460	38 32 90 89 84 83 85 74 76 63 88 88 82			
NCI-H322M 14 NCI-H460 NCI-H4622 COLO Cancer COLO 205 HCC-2998 1 HCT-116 HCT-15 HT29 KM12 SW-620 1 CNS Cancer SF-295 SF-539 SNB-75 U251 11 Melanoma LOX IMVI MALME-3M 1 MALME-3S 11 MDA-MB-435 11 MCAC-257 UACC-62 11 OVCAR-3 -1 OVCAR-4 11 OVCAR-5 21 OVCAR-5 22 OVCAR-8 -1 NCI/ADR-RES -1 SK-0V-3 -1 Renal Cancer -1 TK-10 <t< td=""><td>.32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .88</td><td></td><td></td><td></td></t<>	.32 .90 .89 .84 .83 .85 .74 .76 .63 .88 .88			
NCI-H480 NCI-H522 Colon Cancer COLO 205 HCC-2998 1 HCT-116 HCT-15 HT29 KM12 SW-620 1 CNS Cancer SF-286 11 SNB-19 22 SNB-19 22 SNB-75 U251 11 MALME-3M -1: M14 -1 MALME-3S 11 SK-MEL-2 -1 SK-MEL-5 -8 UACC-257 -4 UACC-257 -1 UACC-257 -1 UACC-257 -2 UACC-257 -3 UACC-257 -4 UACC-257 -4 UACC-257 -5 UACC-257 -6 WAGRON -1 SK-MEL-5 -8	.90 .89 .84 .83 .85 .74 .76 .63 .88 .82			
NCI-H522 -2 Colon Cancer -8 HCC-2998 1 HCT-15 1 HCT-15 1 HCT-15 1 HCT-16 -4 HCT-15 1 HCT-16 -4 HCT-15 1 HCT-16 -4 HCT-15 1 KM12 -5 SW-620 1 CNS Cancer -5 SF-295 -4 SF-205 -4 SNB-75 -1 U251 11 Melanoma -1 MALME-3M -1 M14 1 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-2 -1 SK-MEL-5 -8 UACC-257 -4 UACC-62 11 OVCAR-3 1 OVCAR-4 11 OVCAR-5 22 OVCAR-8 4	.89 .84 .83 .85 .74 .76 .63 .88 .88			
Colon Cancer COLO 205 -84 HCC-2998 1 HCT-116 4 HCT-115 5 HT29 5 SW-620 1 CNS Cancer 5 SF-868 1 SF-268 1 SNB-75 2 US5 1 Melanoma 2 LOX IMVI 8 MALME-3M -11 MDA-MB-435 1 M14 11 MDA-MB-435 1 UACC-62 1 UACC-62 1 OVCAR-3 2 UACC-62 1 OVCAR-4 1 OVCAR-5 21 OVCAR-5 21 OVCAR-8 1 OVCAR-8 1 OVCAR-9 1 OV	.84 .83 .85 .74 .76 .63 .88 .82			
COLO 205 -8. HCC-2998 1 HCT-116 1 HCT-15 1 HT29 1 KM12 1 SW-620 1 CNS Cancer 1 SF-268 11 SF-269 - SF-269 - SNB-19 22 SNB-75 1251 U251 11 MALME-3M -11 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-5 -8 UACC-257 -1 UACC-257 -1 UACC-257 -1 UACC-257 -1 UACC-257 -2 UACC-257 -3 UACC-257 -4 UACC-257 -1 QVCAR-3 11 OVCAR-4 11 OVCAR-5 21 OVCAR-8 4	.83 .85 .74 .76 .63 .88			
HCC-2998 1 HCT-116 4 HCT-15 1 HT2 2 KM12 3 SW-620 1 CNS Cancer 3 SF-295 -1 SF-295 -1 SNB-75 20 U251 11 Melanoma -11 MALME-3M -11 M14 1 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-2 -1 SK-MEL-2 -1 SK-MEL-28 3 SK-MEL-5 -80 UACC-62 0 OVCAR-3 1 OVCAR-4 11 OVCAR-5 21 OVCAR-8 1 NCI/ADR-RES 2 SK-0V-3 -1 Renal Cancer 1 786-0 1 A498 -2 ACHN 1 UO-31 1	.83 .85 .74 .76 .63 .88			
HCT-15 HT29 KM12 SW-620 CNS Cancer SF-208 SNB-75 U251 Melanoma LOX IMV1 MALME-3M LOX IMV1 MALME-3M H14 MDA-MB-435 MALME-3 MALM	.74 .76 .63 .88			
HT29 KM12 SW-620 11 CNS Cancer SF-288 11 SF-295 - SF-539 22 SNB-75 2251 12 Melanoma LOX IMVI 25 MALME-3M -11 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 21 MALME-3 SK-MEL-2 -1- SK-MEL-2	.76 .63 .88			
HT29 KM12 SW-620 11 CNS Cancer SF-288 11 SF-295 - SF-539 22 SNB-75 2251 12 Melanoma LOX IMVI 25 MALME-3M -11 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 11 MDA-MB-435 21 MALME-3 SK-MEL-2 -1- SK-MEL-2	.76 .63 .88			
SW-620 1 CNS Cancer 5F-208 11 SF-205 -4 5F-539 4 SNB-19 22 SNB-75 12 U251 11 12 Mainteen U251 11 12 Mainteen 12 MALME-3M -11 Minteen 41 14 14 MDA-MB-435 11 35 MALME-38 31 35 35 35 35 36 <t< td=""><td>.88</td><td></td><td></td><td></td></t<>	.88			
CNS Cancer SF-268 11 SF-295 - SF-539 2 SNB-75 2 U251 11 Melanoma LOX IMVI 2 MALME-3M -11 MDA-MB-435 11 MDA-MB-435 11 SK-MEL-2 -1- SK-MEL-28 3 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-2 -1- SK-MEL-28 3 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-2 11 VACC-82 11 OVCAR-5 21 OVCAR-4 11 OVCAR-5 21 OVCAR-4 11 OVCAR-5 21 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-9 12 OVCAR-9 12 OVCAR-9 12 SK-OV-3 -12 SK-OV-3 -12 SK-OV-3 12 SK-OV-3 1	.82			
SF-268 11 SF-268 -1 SF-269 -2 SNB-19 22 SNB-75 -2 U251 11 Malanoma -11 MDA-MB-435 11 MALME-3M -11 M14 11 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-28 3 SK-MEL-5 -8 UACC-257 -4 UACC-257 -4 OVCAR-3 4 OVCAR-4 11 OVCAR-5 21 OVCAR-8 12 OVCAR-8 12 OVCAR-8 14 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 OVCAR-8 12 NCI/ADR-RES 12 SK-0V-3 -12 Renal Canoer 12 TK-10 12 U0-31 12 Prostate Canoer <t< td=""><td></td><td></td><td></td><td></td></t<>				
SF-205 SF-205 SNB-19 22 SNB-75 U251 11 Melanoma LOX IMVI MALME-3M 1 M14 MALME-3M -1 M14 MALME-35 11 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-62 11 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-5 22 OVCAR-5 21 OVCAR-8 NCI/ADR-RES SK-0V-3 -1 Renal Cancer 786-0 -1 A498 -2 ACHN -1 UO-31 12 Prostate Cancer -1 Pc-3 12 DU-145 <t< td=""><td></td><td></td><td></td><td></td></t<>				
SF-539 2 SNB-19 22 SNB-75 22 U251 11 Melanoma -11 MALME-3M -11 M14 11 MDA-MB-435 11 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-5 -8 UACC-257 -1 OVCAR-3 10 OVCAR-3 10 OVCAR-4 11 OVCAR-5 21 OVCAR-8 12 NCI/ADR-RES 13 SK-0V-3 -13 Renal Cancer 12 786-0 14 NU/JOR-RES 14 SU/JOR-RES 14 SU/JOR-RES 14 SU/JOR-RES 14 SU/JOR-RES 15 SINI2C 11 TK-10 12 UO-31 12 UP-145 11 Breast Cancer	.29			1
SNB-19 24 SNB-75 11 U251 11 Malanoma -11 LOX IMVI 4 MALME-3M -11 M14 11 MDA-MB-435 11 SK-MEL-2 -14 SK-MEL-28 3 SK-MEL-5 -84 UACC-257 -4 UACC-257 -4 UACC-257 -4 OVCAR-5 22 OVCAR-3 4 OVCAR-4 11 OVCAR-5 21 OVCAR-8 9 NCI/ADR-RES 4 SK-OV-3 -11 Renal Cancer -12 TK-10 12 UO-31 13 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6				1
SNB-75 12 U251 12 Melanoma 12 MALME-3M -11 M14 11 MDA-MB-435 11 SK-MEL-2 -1- SK-MEL-2 -1- SK-MEL-2 -1- SK-MEL-2 -1- VACC-62 11 Ovarian Cancer 16 IGROV1 42 OVCAR-3 10 OVCAR-5 21 OVCAR-5 22 OVCAR-7 -1 Renal Cancer 12 786-0 12 A498 -2 ACHN 12 RXF 393 -3 SN12C 13 TK-10 12 UO-31 12 Prostate Cancer 12 PC-3 13 DU-145 11 Breast Cancer 14 MDA-MB-231/ATCC -6 MDA-MB-231/ATCC -6	.20			
U251 1: Melanoma 1: LOX IMVI 3: MALME-3M -1: M14 10 MDA-MB-435 11 SK-MEL-2 -1: SK-MEL-28 3 SK-MEL-5 -8: UACC-257 -4: UACC-257 -4: OVCAR-3 4: OVCAR-3 4: OVCAR-4 11: OVCAR-5 2! OVCAR-8 4: OVCAR-8 4: OVCAR-8 4: OVCAR-8 4: OVCAR-9 4: NCI/ADR-RES 5: SK-0V-3 -1: Renal Cancer 7: 788-0 4: A498 -2: ACHN 1: RXF 393 -1: TK-10 1: U-31 1: Prostate Cancer 1: PC-3 1: DU-445 1	.06			1
Melanoma -11 MALME-3M -11 M14 11 MDA-MB-435 11 SK-MEL-2 -1- SK-MEL-5 -88 UACC-257 -4 UACC-62 11 Ovarian Cancer 12 OVCAR-3 12 OVCAR-4 11 OVCAR-5 22 OVCAR-8 -1 Renal Cancer -1 788-0 -1 A498 -2 ACHN 13 RXF 393 -3 SN12C 13 TK-10 12 UO-31 12 Prostate Cancer 12 PC-3 13 Breast Cancer 13 Prestat Cancer 14 MDA	.11			1
LOX IMVI MALME-3M -11 MDA-MB-435 11 MDA-MB-435 11 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-28 3 SK-MEL-5 -8 UACC-62 11 Ovarian Cancer 1 IGROV1 44 OVCAR-62 11 OVCAR-5 21 OVCAR-4 11 OVCAR-5 21 OVCAR-4 11 OVCAR-5 21 OVCAR-8 11 OVCAR-8 11 OVCAR-9 11 OV	.49			
MALME-3M -1: M14 10 MDA-MB-435 11 SK-MEL-2 -1. SK-MEL-28 3 SK-MEL-5 -8 UACC-257 -4 UACC-257 -4 OVCAR-4 11 OVCAR-3 4 OVCAR-4 11 OVCAR-5 21 OVCAR-8 4 NCI/ADR-RES 5 SK-0V-3 -1 Renal Cancer -1 788-0 4 A498 -2 ACHN 1 RXF 393 -5 SN12C 13 TK-10 10 UO-31 12 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MDA-MB-231/ATCC -6 MDA-MB-231/ATCC -6				1
M14 11 MDA-MB-435 11 SK-MEL-2 -1 SK-MEL-28 3 SK-MEL-5 -8 UACC-257 -4 VACC-62 11 Ovarian Cancer 12 IGROV1 42 OVCAR-3 12 OVCAR-5 22 OVCAR-8 11 OVCAR-8 12 NCI/ADR-RES 25 SK-0V-3 -11 Renal Cancer 786-0 786-0 12 A498 -2 ACHN 12 RXF 393 -3 SN12C 13 TK-10 12 UO-31 12 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -4	.02			1
MDA-MB-435 11 SK-MEL-28 -1- SK-MEL-28 33 SK-MEL-5 -8 UACC-257 -4 UACC-62 11 Ovarian Cancer 16 IGROV1 42 OVCAR-3 10 OVCAR-5 21 OVCAR-8 11 OVCAR-8 11 OVCAR-8 12 OVCAR-8 12 NCI/ADR-RES 12 SK-0V-3 -11 Renal Cancer 12 786-0 12 SK-0V-3 -11 RXF 393 -2 ACHN 12 SN12C 11 UO-31 11 Prostate Cancer 12 PC-3 11 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1				1
SK-MEL-2 -1. SK-MEL-28 3 SK-MEL-5 -8 UACC-257 -4 UACC-62 10 Ovarian Cancer 10 OVCAR-3 4 OVCAR-3 2 OVCAR-4 11 OVCAR-5 21 OVCAR-8 9 NCI/ADR-RES 4 SK-0V-3 -1 Renal Cancer 7 788-0 4 A498 -2 ACHN 1 RXF 393 - SN12C 13 TK-10 10 UO-31 12 Prostate Cancer 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6	.03			1
SK-MEL-28 3 SK-MEL-28 -8i UACC-257 -4i Ovarian Cancer 10 IGROV1 42 OVCAR-3 41 OVCAR-4 11 OVCAR-5 21 OVCAR-6 21 OVCAR-7 -11 Renal Cancer 11 786-0 42 A498 -22 ACHN 42 RXF 393 -3 SN12C 11 UO-31 12 Prostate Cancer 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6				1
SK-MEL-5 -8 UACC-257 -4 UACC-62 11 Ovarian Cancer 16 IGROV1 42 OVCAR-3 10 OVCAR-4 11 OVCAR-5 21 OVCAR-8 11 OVCAR-8 12 NCI/ADR-RES 42 SK-0V-3 -11 Renal Cancer 12 788-0 12 A498 -2 ACHN 14 RXF 393 -2 SN12C 11 UO-31 12 UO-31 12 Prostate Cancer 12 PC-3 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -8 HS 578T -1				1
UACC-257 UACC-62 10 Ovarian Cancer 10 IGROV1 44 OVCAR-3 41 OVCAR-3 11 OVCAR-4 11 OVCAR-5 21 OVCAR-8 12 NCI/ADR-RES 12 SK-0V-3 -11 Renal Cancer 12 A498 -2 ACHN 14 RXF 393 -2 SN12C 13 TK-10 10 UO-31 11 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -8 HS 578T -4				1
UACC-62 10 Ovarian Cancer 16 IGROV1 44 OVCAR-3 41 OVCAR-4 11 OVCAR-5 21 OVCAR-8 11 OVCAR-9 11 OVCAR-9 12 OVCAR-9 12 OVCAR-8 14 NCI/ADR-RES 12 SK-0V-3 -13 Renal Cancer 12 A498 -2 ACHN 14 RXF 393 -3 SN12C 13 UO-31 14 Prostate Cancer 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1				
Ovarian Cancer 42 IGROV1 42 OVCAR-3 42 OVCAR-4 11 OVCAR-5 22 OVCAR-8 42 NCI/ADR-RES 42 SK-OV-3 -13 Renal Cancer 788-0 788-0 42 A498 -2 ACHN 43 RXF 393 -3 SN12C 11 UO-31 12 Prostate Cancer 12 PC-3 11 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.85			1
IGROV1 4 OVCAR-3 1 OVCAR-4 11 OVCAR-5 22 OVCAR-8 1 OVCAR-8 1 OVCAR-8 1 NCI/ADR-RES 1 Ranal Cancer 1 786-0 1 A498 -2 ACHN 1 RXF 393 - SN12C 1 TK-10 1 Prostate Cancer 1 Prostate Cancer 1 Presst Cancer 1 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1				1
OVCAR-3 1 OVCAR-4 11 OVCAR-5 21 OVCAR-5 21 OVCAR-5 21 OVCAR-8 1 NCI/ADR-RES 2 SK-0V-3 -11 Renal Cancer 1 786-0 4 AXF 393 -2 ACHN 4 RXF 393 -3 SN12C 11 TK-10 12 UO-31 13 Prostate Cancer 14 PC-3 14 Breast Cancer 14 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.38			1
OVCAR-4 11 OVCAR-5 21 OVCAR-8 6 NCI/ADR-RES 5 SK-OV-3 -13 Renal Cancer 788-0 788-0 6 A498 -2 ACHN 11 RXF 393 - SN12C 13 TK-10 10 UO-31 11 Prostate Cancer 11 Prostate Cancer 11 Breast Cancer 11 Breast Cancer 11 MCF7 - MDA-MB-231/ATCC -8 HS 578T -1	.00			1
OVCAR-5 21 OVCAR-8 61 NCI/ADR-RES 51 SK-0V-3 -11 Renal Cancer 786-0 786-0 41 A498 -2 ACHN 42 RXF 393 -3 SN12C 11 TK-10 12 VO-31 11 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.54			1
OVCAR-8 NCI/ADR-RES SK-OV-3 -11 SK-0V-3 -11 11 Renal Cancer 788-0 4 A498 -2 ACHN ACHN 2 ACHN RXF 393 -0 11 TK-10 11 11 Prostate Cancer 12 12 PC-3 11 12 DU-145 11 13 Breast Cancer 12 14 MCF7 4 14 MDA-MB-231/ATCC -6 4	.50			1
NCI/ADR-RES 4 SK-OV-3 -1 Renal Cancer -1 788-0 4 A498 -2 ACHN 4 RXF 393 - SN12C 11 TK-10 11 Prostate Cancer 12 PC-3 11 Breast Cancer 11 MCF7 -4 MDA-MB-231/ATCC -6 HS 578T -1	.40			
SK-OV-3 -1: Renal Cancer 788-0 1 788-0 1 1 ACHN 4 7 RXF 393 -2 3 SN12C 11 1 TK-10 1 1 Prostate Cancer 1 1 Preast Cancer 1 1 MCF7 4 1 MDA-MB-231/ATCC -6 4	.44			
Renal Cancer 788-0 4 788-0 4 -2 ACHN -2 ACHN -2 ACHN -2 ACHN -2 SN12C 10 -1 -2 TK-10 11 12 -2 VO-31 11 12 -2 Prostate Cancer 12 12 13 DU-145 11 14 14 Breast Cancer MCF7 -4 -4 MDA-MB-231/ATCC -6 -6 -6	.23			
788-0 4 A498 -2 ACHN 1 RXF 393 - SN12C 13 TK-10 10 Prostate Cancer 12 PC-3 13 DU-145 11 Breast Cancer 11 MCF7 4 MDA-MB-231/ATCC -8				
A498 -2 ACHN 1 RXF 393 -3 SN12C 11 TK-10 11 UO-31 12 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 12 MCF7 -4 MDA-MB-231/ATCC -6	.85			
RXF 393 - SN12C 11 TK-10 12 Prostate Canoer 12 PC-3 12 DU-145 11 Breast Canoer 11 MCF7 - MDA-MB-231/ATCC -6 HS 578T -6	.71			
RXF 393 - SN12C 11 TK-10 12 Prostate Cancer 12 PC-3 12 DU-145 11 Breast Cancer 11 MCF7 - MDA-MB-231/ATCC -6 HS 578T -1	.64			
TK-10 11 UO-31 11 Prostate Canoer 11 PC-3 11 DU-145 11 Breast Canoer 11 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.71			
UO-31 1: Prostate Cancer 1: PC-3 1: DU-145 11 Breast Cancer 11 MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.03			
Prostate Cancer PC-3 1: PC-3 1: 11: DU-145 11: 11: Breast Cancer MCF7 4: MDA-MB-231/ATCC -6: -6: HS 578T -1: -1:	.11			1
PC-3 1: DU-145 1: Breast Cancer 1: MCF7 4 MDA-MB-231/ATCC -6 HS 578T -1	.14			
DU-145 11 Breast Cancer MCF7 4 MDA-MB-231/ATCC -8 HS 578T -				
Breast Cancer MCF7 - 4 MDA-MB-231/ATCC -6 HS 578T -	.52			
MCF7 4 MDA-MB-231/ATCC -64 HS 578T -1	.48			
MDA-MB-231/ATCC -6- HS 578T -(
HS 578T -	.10			
	.24			
D1-048 1	.70			
	.18			1
	.55			
MDA-MB-468	.23			
Marr	1			
Mean Delta 80	20			
	.30			
rvange 120	.37			
	.30 .37 .45			
	.37	100 5	50 0 -50 -100	-15
	.37 .45	100 0	0 -30 -100	-10
	.37			

							Lo	og10 Cor	ncentration								I
	Cell Line	Time Zero	Ctrl	-8.0			Densiti -5.0	es -4.0	-8.0	-7.0	ercent G -6.0	-5.0	-4.0	GI50	TGI	LC50	
Leuken CCRF HL-60(K-562 MOLT- RPMI-I SR	-CEM ((TB) (-4 (8226 (0.434 0.750 0.269 0.735 0.587 0.441	1.384 1.867 1.586 2.182 2.118 1.333	1.687 1.495 1.850 2.189	1.548 1.749 1.380 1.837 2.289 1.158	1.154 1.790 1.089 1.678 1.647 1.118	0.518 0.384 0.261 0.657 0.459 0.311	0.255 0.112 0.065 0.250 0.220 0.220	112 84 93 77 105 92	117 89 84 76 111 80	76 93 62 65 69 76	9 -49 -3 -11 -22 -29	-41 -85 -76 -66 -63 -84	2.43E-6 2.01E-6 1.54E-6 1.69E-6 1.63E-6 1.76E-6	1.50E-5 4.53E-6 8.95E-6 7.24E-6 5.76E-6 5.25E-6	> 1.00E-4 1.08E-5 4.39E-5 5.13E-5 4.93E-5 2.38E-5	
Non-Sn A549// HOP-6 HOP-7 NCI-H NCI-H NCI-H NCI-H NCI-H	32 0 92 226 0 23 0 322M 0 460 0	Cancer 0.361 0.745 1.114 0.841 0.511 0.874 0.221 0.892	1.574 2.019 1.611 1.812 1.811 2.013 2.147 2.064	1.897 1.506 1.788 1.795 1.895 2.227	1.554 1.924 1.512 1.838 1.743 1.888 2.333 1.841	1.506 1.931 1.396 1.714 1.524 1.937 1.971 1.676	0.437 0.445 0.750 0.594 0.441 0.838 0.167 0.874	0.070 0.020 0.123 0.127 0.013 0.133 0.016 0.068	101 90 79 98 99 90 104 82	98 93 80 103 95 89 110 81	94 93 57 90 78 93 91 67	6 -40 -33 -29 -14 -25 -2	-81 -97 -89 -85 -98 -85 -93 -92	3.19E-6 2.10E-6 1.19E-6 2.16E-6 2.02E-6 2.78E-6 2.26E-6 1.76E-6	1.18E-5 4.99E-6 4.31E-6 5.67E-6 9.08E-6 9.08E-6 9.35E-6	4.43E-5 1.48E-5 2.03E-5 2.35E-5 2.71E-5 3.70E-5 2.35E-5 3.39E-5	
Colon C COLO HCC-2 HCT-1 HCT-1 HCT-1 HT29 KM12 SW-62	205 2998 116 15 20	0.508 0.694 0.195 0.192 0.230 0.508 0.265	1.825 2.320 1.417 1.373 1.350 2.595 1.762	2.287 1.188 1.263 1.332 2.579	1.825 2.188 1.313 1.309 1.275 2.549 1.817	1.551 2.051 0.854 1.166 1.084 2.217 1.657	0.232 0.767 0.030 0.223 0.224 0.410 0.327	0.034 0.047 0.008 0.010 0.014 0.032 0.053	97 98 91 98 99 101	100 92 95 93 98 104	79 83 54 82 76 82 93	-54 4 -85 -3 -19 4	-93 -93 -96 -95 -94 -94 -80	1.65E-6 2.65E-6 1.07E-6 2.55E-6 2.15E-6 2.07E-6 3.04E-6	3.92E-6 1.11E-5 2.45E-6 1.08E-5 9.21E-6 0.45E-6 1.12E-5	9.28E-6 3.61E-5 5.61E-6 3.46E-5 3.30E-5 2.59E-5 4.40E-5	
CNS C: SF-28 SF-53 SNB-1 SNB-7 U251	8 (5 (9 (75 (0.537 0.604 1.012 0.445 0.886 0.334	1.918 2.296 2.615 1.798 1.716 1.474	2.074 2.324 1.795 1.563	1.854 2.166 2.446 1.818 1.647 1.576	1.704 2.100 2.357 1.470 1.499 1.223	0.660 0.588 0.714 0.570 0.938 0.348	0.040 0.019 0.010 0.013 0.182 0.020	99 87 82 100 82 105	95 92 89 101 92 109	85 88 84 76 74 78	9 -3 -29 9 6 1	-93 -97 -99 -97 -79 -94	2.86E-6 2.64E-6 1.99E-6 2.44E-6 2.25E-6 2.31E-6	1.22E-5 9.33E-6 5.50E-6 1.22E-5 1.18E-5 1.03E-5	3.81E-5 3.18E-5 1.97E-5 3.61E-5 4.53E-5 3.44E-5	
Melano LOX IN MALM MD4-M SK-ME SK-ME SK-ME UACC UACC	MVI (IE-3M (MB-435 (EL-2 EL-28 (EL-28 (EL-5 (-257)	0.333 0.572 0.420 0.592 1.031 0.753 0.632 1.062 0.631	2.312 1.196 1.512 2.405 2.081 2.248 2.939 1.992 2.445	1.156 1.338 2.282 2.030 2.091 2.848 1.973	1.171 1.408	2.147 1.097 1.289 2.184 1.917 2.036 2.601 1.901 2.091	0.023 0.292 0.097 0.484 0.792 0.726 0.033 0.844 0.149	0.009 0.009 0.006 0.001 0.024 0.005 0.009 0.034 -0.005	97 94 84 93 95 90 98 98 94	96 90 99 95 97 99 102 101	92 84 80 88 84 86 85 90 80	-93 -49 -77 -18 -23 -4 -95 -21 -76	-97 -98 -99 -100 -98 -99 -99 -97 -100	1.68E-6 1.81E-6 2.27E-6 2.09E-6 2.51E-6 1.57E-6 2.31E-6 1.56E-6	3.13E-6 4.29E-6 3.22E-6 6.73E-6 9.10E-6 2.98E-6 6.52E-6 3.26E-6	5.84E-6 1.05E-5 6.73E-6 2.45E-5 3.05E-5 5.64E-6 2.43E-5 6.78E-6	
IGROV OVCA OVCA OVCA OVCA	R-3 (R-4 (R-5 (R-8 (DR-RES (0.375 0.417 0.826 0.581 0.581 0.581 0.487 0.894	1.737 1.450 1.664 1.340 2.200 1.677 1.865	1.478 1.576 1.245 2.228 1.683	1.691 1.471 1.613 1.242 2.213 1.636 1.849	1.586 1.155 1.448 1.226 2.092 1.546 1.754	0.412 0.264 0.825 0.574 0.642 0.415 0.949	0.024 0.015 0.034 0.023 0.176 0.093 0.067	99 103 90 87 102 100 90	97 102 94 87 101 96 98	89 71 74 85 93 89 88	3 -37 -1 4 -15 6	-94 -97 -96 -96 -70 -81 -93	2.83E-6 1.58E-6 2.12E-6 2.54E-6 3.04E-6 2.37E-6 2.92E-6	1.07E-5 4.58E-6 9.96E-6 9.66E-6 1.12E-5 7.19E-6 1.14E-5	3.52E-5 1.67E-5 3.32E-5 3.27E-5 5.38E-5 3.40E-5 3.69E-5	
Renal C 788-0 A498 ACHN CAKI-1 RXF 3 SN12C TK-10 UO-31	1 1 93 1 C 1	0.403 1.422 0.379 0.767 0.685 0.391 0.865 0.608	1.704 2.138 1.616 2.725 1.324 1.688 1.691 2.046	2.082 1.521 2.463 1.379 1.695 1.602	1.602 2.081 1.612 2.561 1.393 1.704 1.595 1.956	1.343 1.987 1.364 2.574 1.248 1.544 1.762 1.833	0.128 0.645 0.341 0.594 0.528 0.079 0.962 0.277	0.005 0.014 0.006 0.031 0.022 0.002 0.117 0.035	87 92 87 109 101 89 94	92 92 100 92 111 101 88 94	72 79 80 92 88 89 109 85	-69 -55 -10 -23 -23 -80 12 -54	-99 -99 -96 -97 -97 -87 -94	1.44E-6 1.64E-6 2.33E-6 2.39E-6 1.70E-6 4.03E-6 1.79E-6	3.25E-6 3.90E-6 7.71E-6 6.35E-6 6.18E-6 3.36E-6 1.32E-5 4.07E-6	7.36E-6 9.23E-6 2.82E-5 2.36E-5 2.31E-5 6.65E-6 4.25E-5 9.29E-6	
Prostate PC-3 DU-14		0.440 0.338	1.367 1.482		1.361 1.542	1.023 1.444	0.388 0.558	0.023	95 105	99 105	63 97	-12 19	-95 -91	1.49E-6 4.00E-6	6.93E-6 1.49E-5	2.88E-5 4.24E-5	
HS 570 BT-540 T-47D	MB-231/ATCC	0.346 0.547 0.815 1.139 0.703 0.640	2.183 1.431 1.585 1.947 1.578 1.326	1.428 1.617 1.789 1.451	1.934 1.460 1.619 1.840 1.490 1.353	1.746 1.367 1.478 1.777 1.361 1.095	0.401 0.246 0.724 0.463 0.701 0.487	0.081 0.019 0.370 0.007 0.396 0.095	87 100 104 80 85 102	86 103 104 87 90 104	76 93 86 79 75 66	3 -55 -11 -59 0 -24	-77 -97 -55 -99 -44 -85	2.28E-6 1.95E-6 2.35E-6 1.62E-6 2.16E-6 1.52E-6	1.09E-5 4.24E-6 7.67E-6 3.72E-6 9.89E-6 5.43E-6	4.62E-5 9.23E-6 7.83E-5 8.55E-6 > 1.00E-4 2.67E-5	
60 60 60 60 60 60 60 60 60 60	s -7 og ₁₀ of Sample Con — HL-60(TB)	-6 icentration		-5622		100 (#%00) 00 00 00 00 00 00 00 00 00	-9	-e Log ₁₀ of	-7 -7 Sample Conc HOP-82- NCI-H522-		-5 Molar)	P-02	<u>۸</u>	100 60 8 9 0 -100 9 COLO 205 HOT-15E SW-620	Colon Ci		10
650 960 960 	CNS C.	-6 icentration	SF	539		MDA-M	-9 KIMVI9 B 435		Melanc 	-5 entration (M14	A 	IGROV1-G	Ovarian C Ovarian C I age of Sample Conc OVCAR-3- OVCAR-3-		
650 870 	Renal C	-6 icentration	A	CHN-		100 6 50 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9		¢	Prostate (7 1 Sample Conc DU-145-		-s Molar)			100 50 0 -100 9 MCF7 8 T-549 	Breast C		



²f

Leukemia CCRF-CEM HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-62 HOP-62 HOP-92 NCI-H226 NCI-H226 NCI-H227 NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M Colo 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-3 UACC-257 UACC-62 OvcaR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	36.25 34.35 16.28 20.12 21.02 43.86 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.65 71.54							
HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-62 HOP-62 HOP-92 NCI-H236 NCI-H236 NCI-H230 NCI-H226 NCI-H226 NCI-H227 Colon Cancer COLO 205 HCC-2908 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-208 SF-208 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 U	34.35 16.28 20.12 21.02 43.86 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 48.07 70.30 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 63.40 77.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
K-562 MOLT-4 RPMI-8228 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-82 HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H328 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-288 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-3 UACC-257 UACC-82 OvcAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	16.28 20.12 21.02 43.86 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
MOLT-4 RPMI-8228 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-82 HOP-92 NCI-H228 NCI-H232M NCI-H322M NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-82 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-7 NCI-MEL SK-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer MCF7	20.12 21.02 43.86 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 48.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
RPMI-8226 SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-82 HOP-92 NCI-H226 NCI-H322M NCI-H32 NCI-H32 NCI-H32 NCI-H32 NCI-H32 NCI-H32 RM14 MDA-MB-435 SK-MEL-3 SK-MEL-3 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-42 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-6 OVCAR-7 Renal Cancer	21.02 43.88 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.88 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 63.40 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
SR Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-62 HOP-62 HOP-62 NCI-H226 NCI-H322M NCI-H322M NCI-H522 Colon Cancer COLO 205 HCT-116 HCT-2908 HCT-15 HT20 KM12 SW-820 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-257 UACC-82 OvcaR-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-6 OVCAR-7 NCI/ADR-RES SK-0V-3 Renal Cancer	43.86 56.73 43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
Non-Small Cell Lung Cancer A549/ATCC EKVX HOP-82 HOP-92 NCI-H226 NCI-H322M NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-208 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-28 SK-MEL-20 SK-MEL-28 SK-MEL-20 SK-MEL-20 SK-MEL-20 SK-MEL-20 SK-MEL-20 SK-MEL-20 SK-MEL-30 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES <td< td=""><td>56.73 43.08 85.54 84.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 48.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65</td><td></td><td></td><td></td><td>Ť.</td><td></td><td></td><td></td></td<>	56.73 43.08 85.54 84.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 48.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
A549/ATCC EKVX HOP-82 HOP-92 NCI-H228 NCI-H228 NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H322M NCI-H324 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-115 HT29 KM12 SW-620 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
EKVX HOP-82 HOP-92 NCI-H226 NCI-H227 NCI-H227 NCI-H322M NCI-H460 NCI-H460 NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-820 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 SK-MEL-3 OVCAR-4 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-5 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	43.08 85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
HOP-82 HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H460 NCI-H522 Colon Cancer COLO 205 HCC-2908 HCT-15 HT29 KM12 SW-920 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UAC	85.54 64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
HOP-92 NCI-H238 NCI-H238 NCI-H232M NCI-H322M NCI-H322M Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-920 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-82 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	64.91 47.72 37.39 74.81 36.68 31.16 78.60 66.88 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
NCI-H226 NCI-H23 NCI-H322M NCI-H460 NCI-H322M Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-820 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-5 SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	47.72 37.39 74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.65				Ť.			
NCI-H322M NCI-H460 NCI-H622 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT20 KM12 SW-620 CNS Cancer SF-208 SF-205 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer <	74.81 36.68 31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.	•		
NCI-H460 NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-116 HT29 KM12 SW-820 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 SK-MEL-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-5 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	36.68 31.16 78.60 66.86 32.14 42.93 48.73 48.83 70.33 71.62 49.07 70.30 63.40 62.63 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
NCI-H522 Colon Cancer COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-285 SF-539 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-257 UACC-257 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-7 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer	31.16 78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
Colon Cancer COLO 205 HCC-2908 HCT-116 HCT-15 HT20 KM12 SW-620 CNS Cancer SF-208 SF-208 SF-208 SF-209 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-257 UACC-257 UACC-262 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	78.60 66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-268 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 UACC-257 UACC	66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.85				Ť.			
HCC-2008 HCT-116 HCT-15 HT29 SW-620 CNS Cancer SF-268 SF-295 SF-539 SNB-75 U251 Melanoma LOX IMV1 MALME-30 M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 OVarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	66.86 32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.85				Ť.			
HCT-116 HCT-15 HT29 KM12 SW-620 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	32.14 42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
HCT-15 HT29 KM12 SW-620 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMV1 MALME-3M M14 MDA-MB-435 SK-MEL-22 SK-MEL-23 SK-MEL-23 SK-MEL-23 SK-MEL-25 UACC-257 SK-0V-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	42.93 48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.65				Ť.			
HT29 KM12 SW-620 CNS Cancer SF-205 SF-295 SF-295 SF-539 SNB-75 U251 Melanoma LOX IMV1 MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 OVCAR-4 UACC-257 UACC-62 OVCAR-3 OVCAR-4 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	48.73 46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
KM12 SW-820 CNS Cancer SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	46.83 70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
SW-620 CNS Cancer SF-208 SF-208 SF-295 SF-539 SNB-75 U251 Melanoma LOX IMV1 MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-28 SK-MEL-28 SK-MEL-28 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	70.33 71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
CNS Cancer SF-208 SF-295 SF-539 SNB-75 U251 Melanoma LOX IMV1 MALME-3M M14 MDA-MB-435 SK-MEL-3 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	71.62 49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				Ť.			
SF-288 SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
SF-295 SF-539 SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 UACC-257 SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	49.07 70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				Ť.			
SF-539 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	70.30 63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85				-			
SNB-19 SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 UACC-257 UACC-25	63.40 62.53 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				-			
SNB-75 U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	62.63 48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.65				=			
U251 Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	48.57 57.27 80.24 58.96 73.41 71.59 79.08 54.29 78.71 58.85							
Melanoma LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-4 OVCAR-4 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	57.27 80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.65				-			
LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.65							
MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	80.24 58.96 73.41 71.59 79.06 54.29 78.71 58.65							
M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-0V-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	58.96 73.41 71.59 79.06 54.29 78.71 58.65							
MDA-MB-435 SK-MEL-2 SK-MEL-2 SK-MEL-5 UACC-257 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	73.41 71.59 79.06 54.29 78.71 58.65							I
SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	71.59 79.06 54.29 78.71 58.65							
SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	79.06 54.29 78.71 58.65							
SK-MEL-5 UACC-257 UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	54.29 78.71 58.65							
UACC-257 UACC-82 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	78.71 58.65							
UACC-62 Ovarian Cancer IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A408 ACHN RXF 303 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	58.65							
Ovarian Cancer IGROV1 OVCAR-3 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7								
IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	71.54				1			
OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7								
OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	35.25							
OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	46.05							
OVCAR-8 NCI/ADR-RES SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	89.14							
NCI/ADR-RES SK-OV-3 Renal Cancer 786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	49.98				-			
SK-OV-3 Renal Cancer 788-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	46.06							
786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	94.11							
786-0 A498 ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7								
ACHN RXF 393 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	48.29				—			
RXF 303 SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	76.21							
SN12C TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	52.13				•			
TK-10 UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	72.36							
UO-31 Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	61.42				-			
Prostate Cancer PC-3 DU-145 Breast Cancer MCF7	60.13				•			
PC-3 DU-145 Breast Cancer MCF7	56.97				1			
DU-145 Breast Cancer MCF7								
Breast Cancer MCF7	34.90							
MCF7	56.86			1	1			
	25.52					_		
MDA-MB-231/ATCC	79.35							
HS 578T	70.89					1		
BT-549	100.35					1		
T-47D	32.01			_	-			
MDA-MB-468				-			1	
Mana	39.93			_		•		
Mean Delta	39.93			-				I
	39.93 56.16			-	-			
Range	39.93 56.16 39.88			_				
	39.93 56.16			-		=		
	39.93 56.16 39.88			-		=		
	39.93 56.16 39.88 84.07	150	100	-		=		
	39.93 56.16 39.88 84.07	150	100	50	0	-50	-100	-15

References

1. Chen L, Fu W, Feng C, Qu R, Tong L, Zheng L, et al. Structure-based design and synthesis of 2, 4diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. Eur J Med Chem 2017;140:510– 527.

2. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al. Discovery of 3-(2, 6-dichloro-3, 5dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54(20):7066–7083.

3. Bhattarai D, Jung JH, Han S, Lee H, Oh SJ, Ko HW, et al. Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors. Eur J Med Chem 2017;125:1036–1050.

4. El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G. Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A new benzothiazole derivative with remarkable broad-spectrum antiproliferative activity. ChemMedChem. 2016;11(15):1587–1595.

5. Reaction Biology Corporation. Available from:

http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx [last accessed 6 December 2022].

6. El-Damasy AK, Lee JH, Seo SH, Cho NC, Pae AN, Keum G. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities. Eur J Med Chem 2016;115:201–216.

7. DTP Human Tumor Cell Line Screen Process: Available from: <u>https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm</u> [last accessed 6 December 2022].

8. Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66(11):5790–5797.

9. Zhou TJ, Parillon L, Li F, Wang YH, Keats J, Lamore S, et al. Crystal structure of the T315I mutant of abl kinase. Chem Biol Drug Des 2007;70(3):171–181.